prikaz prve stranice dokumenta Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu
  Download
PDF 2.4 MB
doctoral thesis
Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu
Zagreb: University of Zagreb, School of Medicine, 2023. urn:nbn:hr:105:092923
Bašić-Kinda, Sandra
University of Zagreb
School of Medicine

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bašić Kinda, S. (2023). Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu (Doctoral thesis). Zagreb: University of Zagreb, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:092923

Bašić Kinda, Sandra. "Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu." Doctoral thesis, University of Zagreb, School of Medicine, 2023. https://urn.nsk.hr/urn:nbn:hr:105:092923

Bašić Kinda, Sandra. "Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu." Doctoral thesis, University of Zagreb, School of Medicine, 2023. https://urn.nsk.hr/urn:nbn:hr:105:092923

Bašić Kinda, S. (2023). 'Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu', Doctoral thesis, University of Zagreb, School of Medicine, accessed 22 November 2024, https://urn.nsk.hr/urn:nbn:hr:105:092923

Bašić Kinda S. Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu [Doctoral thesis]. Zagreb: University of Zagreb, School of Medicine; 2023 [cited 2024 November 22] Available at: https://urn.nsk.hr/urn:nbn:hr:105:092923

S. Bašić Kinda, "Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu", Doctoral thesis, University of Zagreb, School of Medicine, Zagreb, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:105:092923

Metadata
TitleIzraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu
Title (english)Expresion and clinical importance of galektin-3, VEGF and NF-κB in diffuse large B-cell lymphoma
AuthorSandra Bašić-Kinda
MentorIgor Aurer (mentor)
Committee memberVlatko Pejša (predsjednik povjerenstva)
Committee memberSlavko Gašparov (član povjerenstva)
Committee memberSlobodanka Ostojić Kolonić (član povjerenstva)
GranterUniversity of Zagreb
School of Medicine
Zagreb
Defense date and country2023-06-12, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Universal decimal classification
(UDC)		616 - Pathology. Clinical medicine
Abstract
Uvod i svrha rada: Galektin-3 je jedini galektin kimerične strukture. Uključen je u važne stanične procese: regulaciju proliferacije stanica, apoptozu i angiogenezu.Više od 50% DLBCL-a izražava galektin-3. Preliminarni rezultati pokazuju da galektin-3 + DLBCL ima lošiju prognozu. Svrha je ovog rada usporediti biološke i kliničke karakteristike galektin3+ i galektin-3- DLBCL-a i ishode liječenja. Materijali i metode: U novodijagnosticiranih bolesnika s DLBCL-om, liječenih R-CHOP-om ili sličnim protokolom analizirali smo kliničke karakteristike (dob, spol, IPI, odgovor na liječenje, EFS i OS). Imunohistokemijski smo odredili izražaj galektina-3, BCL2, VEGF i NF-κB i stanično podrijetlo tumora. Rezultati: Uključeno je ukupno123 bolesnika uz medijan praćenja 68 mjeseci. Galektin-3 bio je pozitivan kod 69 (56,1%). Bolesnici koji su imali viši IPI (p=0,002), ABC fenotip (p=0,029) i pojačani izražaj NF-κB (p=0,016) češće su izražavali galektin-3. Izražaj galektina 3 nije značajno utjecao na OS i EFS. BCL2 + bolesnici imali su značajno lošiji ishod ukoliko su istovremeno bili galektin3+ (dvogodišnji EFS 44% vs 73% (p=0,002) i OS 50% vs 74% (p=0,006). Značajno više VEGF + tumora imalo je ABC fenotip. Značajno lošiji ishod imali su VEGF+ DLBCL GCB ali ne i ABC imunofenotipa (p=0,001).U multivarijatnoj analizi BCL2 je bio jedini značajni faktor za EFS i OS, dok izražaj galektina-3 pokazuje trend za lošiji ishod (p=0,068 za EFS i p=0,093 za OS). Zaključak: Naši rezultati u skladu su s eksperimentalnim podacima koji pokazuju da NF-κB stimulira izražaj galektina-3 i da galektin-3 dodatno potencira antiapoptotički učinak BCL2. Galektin-3 je češće izražen kod uznapredovalog stadija DLBCL-a i kod ABC fenotipa, što je u skladu s njegovim potencijalnim proliferativnim i antiapoptotičkim učinkom i njegovim izražajem na memorijskim stanicama.
Abstract (english)
Introduction and aim: Galektin-3 is the only chimeric galectins. It is involved in crucial cellular processes including cell proliferation, apoptosis and angiogenesis. More than 50% of DLBCL express galectin-3. Preliminary results showed that galectin 3+ DLBCL have inferior prognosis. The purpose of this study is to compare biological and clinical characteristics of galectin-3+ and galectin-3- DLBCL and outcomes of treatment. Material and methods: In newly diagnosed DLBCL patients treated with R-CHOP like regimens we analyzed clinical characteristics (age, sex, IPI, response to treatment, EFS and OS). Expression of gal-3, BCL2, VEGF and NF-κB and cell of origin were determined by immunochemistry. Results: 123 patients were included with a median follow up 68 months. Galectin-3 was positive in 69 (56,1%). Patient with high IPI (p=0,002), ABC phenotype (p=0,029) and NF-κB + (p=0,016) expressed galektin-3 more frequently. Expression of galektin-3 did not affect OS and EFS. BCL2 + patients fared significantly worse if they coexpressed galektin-3 (2-y EFS 44% vs 73% (p=0,002) and OS 50% vs 74% (p=0,006)). Significantly higher number of VEGF + tumors were of ABC origin. Outcomes of VEGF + GCB, but not ABC DLBCLs were significantly inferior (p=0,001). In multivariant analysis BCL2 was only significant factor for EFS and OS, while galectin-3 showed trend for worse outcomes (p=0,068 for EFS and p=0,093 for OS). Conclusion: Our results are consistent with experimental data showing that NF-KB stimulates galectin-3 expression and that galectin-3 potentiates antiapoptotic effect of BCL2. Galectin-3 is more commonly expressed in advanced stage DBCL and also in ABC phenotype, which is in accordance with his potential proliferative and antiapoptotic effect and its expression on memory cells.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:105:092923
Study programmeTitle: Biomedicine and Health Sciences
Study programme type: university
Study level: postgraduate
Academic / professional title: doktor/doktorica znanosti, područje biomedicine i zdravstvo (doktor/doktorica znanosti, područje biomedicine i zdravstvo)
Type of resourceText
Extent81 str.
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2023-07-07 09:43:09